In contrast, CASP12 had significantly higher expression in CESC, COAD, ESCA, KIRP, Prostate adenocarcinoma (PRAD), READ, Skin Cutaneous Melanoma (SKCM), STAD, and TGCT and lower expression in BLCA, BRCA, Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (DLBC), KIRC, Lung adenocarcinoma (LUAD), Lung squamous cell carcinoma (LUSC), Ovarian serous cystadenocarcinoma (OV), PAAD, THCA, Thymoma(THYM), UCEC, and Uterine Carcinosarcoma(UCS) (all P < 0.05). This evidence concerns the gene CASP12 and bladder transitional cell carcinoma.